Hematopoietic stem cell transplantation for severe combined immune deficiency.
Hematopoietic stem cell transplantation (HSCT) has been the definitive therapy for severe combined immune deficiency (SCID) since the first successful transplant for SCID in 1968. Improvements in the use of HSCT to treat patients with SCID are continuing. For example, during the last 5 years, the first successful in-utero HSCT, and the first success with gene therapy have occurred in patients with SCID. Debate still continues about the role of pretransplantation therapy for SCID patients, and the biology of post-HSCT immune reconstitution is under investigation.
Weinberg
K I
KI
Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital Los Angeles, 4650 Sunset Blvd., MS#84, Los Angeles, CA 90027, USA.
Kapoor
N
N
Shah
A J
AJ
Crooks
G M
GM
Kohn
D B
DB
Parkman
R
R
D015316:Genetic Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016511:Severe Combined Immunodeficiency / Q000276:immunology / Q000601:surgery / Q000628:therapy*